Illumina (NASDAQ:ILMN) Director Keith Meister Sells 106,543 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 106,543 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $225.46, for a total value of $24,021,184.78. Following the transaction, the director owned 1,172,289 shares in the company, valued at $264,304,277.94. This trade represents a 8.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Illumina Trading Up 1.3%

ILMN opened at $227.69 on Friday. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $231.81. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The business has a fifty day simple moving average of $192.98 and a 200-day simple moving average of $155.18. The firm has a market cap of $34.38 billion, a P/E ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the business earned $1.19 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent research reports. Canaccord Genuity Group raised their price objective on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research note on Monday, August 3rd. JPMorgan Chase & Co. upped their target price on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Piper Sandler reissued an “overweight” rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Finally, Guggenheim upped their price objective on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $188.40.

Institutional Trading of Illumina

Large investors have recently made changes to their positions in the company. California State Teachers Retirement System lifted its stake in Illumina by 16,869.5% in the second quarter. California State Teachers Retirement System now owns 40,144,099 shares of the life sciences company’s stock worth $7,058,537,000 after acquiring an additional 39,907,533 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Illumina in the 2nd quarter valued at approximately $3,374,423,000. Primecap Management Co. CA purchased a new stake in shares of Illumina in the 2nd quarter valued at approximately $617,981,000. Jupiter Topco LLC acquired a new stake in shares of Illumina in the 2nd quarter valued at $358,652,000. Finally, WCM Investment Management LLC raised its holdings in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.